Stock listing
AGIO Stock Price, News, Filings & Events — Agios Pharmaceuticals, Inc.
Selected listing: AGIO · BIVA · MXN · MX
This page tracks Agios Pharmaceuticals, Inc.'s AGIO:BIVA listing on BIVA in MXN for MX, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following AGIO:BIVA. AGIO:BIVA is the stock-level entry point for investors researching Agios Pharmaceuticals, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Agios Pharmaceuticals, Inc. is a public company traded under the ticker AGIO in the American market. The company has a market capitalization of approximately $2.16 billion. Agios focuses on developing innovative therapies for patients with genetically defined diseases and cancer.
- Ticker
- AGIO:BIVA
- Asset type
- Stock
- Market cap
- $1.99B
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- BIVA
- Currency
- MXN
Agios Pharmaceuticals, Inc. AGIO:BIVA stock context
This page tracks Agios Pharmaceuticals, Inc.'s AGIO:BIVA listing on BIVA in MXN for MX, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following AGIO:BIVA. AGIO:BIVA is the stock-level entry point for investors researching Agios Pharmaceuticals, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Agios Pharmaceuticals, Inc. is a public company traded under the ticker AGIO in the American market. The company has a market capitalization of approximately $2.16 billion. Agios focuses on developing innovative therapies for patients with genetically defined diseases and cancer.
Latest news from Agios Pharmaceuticals, Inc.
Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
July 30, 2026
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
July 21, 2026
U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease
July 7, 2026
Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET
June 29, 2026
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell...
June 13, 2026
Agios Pharmaceuticals, Inc. earnings calls
Agios Pharmaceuticals, Inc. (AGIO) Q2 2026 Earnings Call
July 30, 2026 · Replay with transcript and chapters
Agios Pharmaceuticals, Inc. (AGIO) Q1 2026 Earnings Call
April 29, 2026 · Replay with transcript and chapters
Agios Pharmaceuticals, Inc. (AGIO) Q4 2025 Earnings Call
February 12, 2026 · Replay with transcript and chapters
Agios Pharmaceuticals, Inc. (AGIO) Q3 2025 Earnings Call
October 30, 2025 · Replay with transcript and chapters
Agios Pharmaceuticals, Inc. (AGIO) Q2 2025 Earnings Call
July 31, 2025 · Replay with transcript and chapters
Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call
May 1, 2025 · Replay with transcript and chapters
Research Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. investor report
Review AI stock analysis and investor report context for AGIO:BIVA.
Agios Pharmaceuticals, Inc. company profile
View the public company page for Agios Pharmaceuticals, Inc. on 6ix.
Agios Pharmaceuticals, Inc. news
Read company news and market updates connected to Agios Pharmaceuticals, Inc..
Agios Pharmaceuticals, Inc. investor events
Find investor webinars, events, and replay context for Agios Pharmaceuticals, Inc..
Alternate listings
AGIO:NASDAQ
US · USD
Alternate listing for Agios Pharmaceuticals, Inc.; the primary context on this page is AGIO:BIVA.
A1W2RM:LS
DE · EUR
Alternate listing for Agios Pharmaceuticals, Inc.; the primary context on this page is AGIO:BIVA.
A1W2RM:LSX
DE · EUR
Alternate listing for Agios Pharmaceuticals, Inc.; the primary context on this page is AGIO:BIVA.
8AP:GETTEX
DE · EUR
Alternate listing for Agios Pharmaceuticals, Inc.; the primary context on this page is AGIO:BIVA.
0HB0:LSE
GB · USD
Alternate listing for Agios Pharmaceuticals, Inc.; the primary context on this page is AGIO:BIVA.
AGIO:BMV
MX · MXN
Alternate listing for Agios Pharmaceuticals, Inc.; the primary context on this page is AGIO:BIVA.
8AP:TRADEGATE
DE · EUR
Alternate listing for Agios Pharmaceuticals, Inc.; the primary context on this page is AGIO:BIVA.
AGIO:BOATS
US · USD
Alternate listing for Agios Pharmaceuticals, Inc.; the primary context on this page is AGIO:BIVA.
8AP:BX
CH · CHF
Alternate listing for Agios Pharmaceuticals, Inc.; the primary context on this page is AGIO:BIVA.
8AP:DUS
DE · EUR
Alternate listing for Agios Pharmaceuticals, Inc.; the primary context on this page is AGIO:BIVA.
8AP:FWB
DE · EUR
Alternate listing for Agios Pharmaceuticals, Inc.; the primary context on this page is AGIO:BIVA.
8AP:MUN
DE · EUR
Alternate listing for Agios Pharmaceuticals, Inc.; the primary context on this page is AGIO:BIVA.